$10.44
-6.8%Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Wall Street analysts project that CLYM stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 20.00, with estimates ranging from a low of 17.00 to a high of 25.00.
The consensus 1-year price target stands at 20.00, with estimates ranging from a low of 17.00 to a high of 25.00.
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Declining expectations indicate headwinds—investigate whether temporary or structural issues.
Wide estimate range reveals significant forecast uncertainty and potential volatility.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Declining estimates with wide disagreement: Analysts projecting contraction without consensus signals significant business uncertainty—exercise caution.
Declining expectations indicate headwinds—investigate whether temporary or structural issues.
Good analyst coverage ensures reliable estimates with diverse professional perspectives.
Wide estimate range reveals significant forecast uncertainty and potential volatility.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Declining estimates with wide disagreement: Analysts projecting contraction without consensus signals significant business uncertainty—exercise caution.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Significant contraction projected—major business challenges or industry disruption likely.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
During the last 12 months, insiders have purchased $1.14M and sold $1.85M worth of CLYM shares, resulting in $713K of net selling activity.
0
0.00
0
0.00
+0
+$0
321.7K
779.62K
150.0K
879.38K
-100K
-$100K
0
0.00
0
0.00
+0
+$0
280.0K
361.20K
621.9K
974.69K
-613K
-$613K
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$831K
Levin Andrew David
Director
$52K
Thomas Stephen Basil
Director
$52K
Williams Douglas E
Director
$52K
Dunn Judith
Director
$52K
Wilson Perrin Megan
Officer: Chief Business Officer
$948K
Thomas Stephen Basil
Director
$879K
Brennan Aoife
Director, Officer: President And Ceo
$25K
Pimblett Emily
Officer: Svp, Finance & Cao
$2K
Slightly bearish with $713K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
5 insider buyers vs. 4 sellers. More insiders buying than selling indicates positive sentiment.
Continue your CLYM research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.